We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cybin Inc | AMEX:CYBN | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.002 | -0.57% | 0.35 | 0.3502 | 0.34 | 0.3502 | 2,136,168 | 00:53:06 |
CYBIN INC. | ||||||||||||||
(Registrant) | ||||||||||||||
Date: | October 26, 2023 | By: | /s/ Doug Drysdale | |||||||||||
Name: | Doug Drysdale | |||||||||||||
Title: | Chief Executive Officer |
Item 1 | Name and Address of Company Cybin Inc. (the “Company” or “Cybin”) 100 King Street West, Suite 5600 Toronto, Ontario M5X 1C9 | ||||
Item 2 | Date of Material Change October 23, 2023 | ||||
Item 3 | News Release A joint news release announcing the material change referred to in this report was disseminated on October 23, 2023, through Business Wire and has been filed under Cybin’s profile on SEDAR+ at www.sedarplus.com. | ||||
Item 4 | Summary of Material Change On October 23, 2023, Cybin and Small Pharma Inc. (“Small Pharma”) completed the previously-announced acquisition by Cybin of Small Pharma by way of a plan of arrangement under the provisions of the Business Corporations Act (British Columbia) (the “Arrangement”). As a result of the Arrangement, Small Pharma became a wholly owned subsidiary of Cybin. | ||||
Item 5 | Full Description of Material Change On August 28, 2023, Cybin and Small Pharma entered into a definitive arrangement agreement (the “Arrangement Agreement”) providing for the acquisition by Cybin of all issued and outstanding securities of Small Pharma pursuant to a plan of arrangement under Division 5 of Part 9 of the Business Corporations Act (British Columbia). On October 23, 2023, the Arrangement was effected. As a result of the Arrangement, Small Pharma became a wholly owned subsidiary of Cybin. Under the terms of the Arrangement, Cybin issued to each former Small Pharma shareholder 0.2409 common shares of Cybin (“Cybin Shares”) for each Small Pharma common share (“Small Pharma Share”) held. Cybin issued an aggregate of approximately 80,945,254 Cybin Shares pursuant to the Arrangement. Small Pharma Shares were delisted from the TSX Venture Exchange at the close of trading on October 25, 2023, and subsequently removed from the OTCQB Venture Market. Small Pharma will apply to cease to be a reporting issuer in each of the provinces and territories in Canada. Pursuant to the terms of the Arrangement Agreement, upon completion of the Arrangement, Mr. George Tziras was appointed to Cybin’s board of directors and will serve as Cybin’s Chief Business Officer. | ||||
Item 6 | Reliance on Subsection 7.1(2) of National Instrument 51-102 Not applicable. |
Item 7 | Omitted Information Not applicable. | ||||
Item 8 | Executive Officer Further information regarding the matters described in this report may be obtained from Gabriel Fahel, Chief Legal Officer of Cybin, who is knowledgeable about the details of the material change and may be contacted at 1-866-292-4601. | ||||
Item 9 | Date of Report October 25, 2023 |
1 Year Cybin Chart |
1 Month Cybin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions